Compounds > omega-n-methylarginine
Page last updated: 2024-09-03

omega-n-methylarginine and cp 101,606

omega-n-methylarginine has been researched along with cp 101,606 in 1 studies

Compound Research Comparison

Studies
(omega-n-methylarginine)		Trials
(omega-n-methylarginine)		Recent Studies (post-2010)
(omega-n-methylarginine)		Studies
(cp 101,606)		Trials
(cp 101,606)		Recent Studies (post-2010) (cp 101,606)
4,41134433693631

Protein Interaction Comparison

ProteinTaxonomyomega-n-methylarginine (IC50)cp 101,606 (IC50)
Glutamate receptor ionotropic, NMDA 2DHomo sapiens (human)0.007
Glutamate receptor ionotropic, NMDA 3BHomo sapiens (human)0.007
Cytochrome P450 2D6Homo sapiens (human)4.25
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)5.7
Prolyl endopeptidaseSus scrofa (pig)0.007
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)5.7
Delta-type opioid receptorMus musculus (house mouse)0.007
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)0.073
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)5.7
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)0.0338
Glutamate receptor ionotropic, NMDA 1Homo sapiens (human)0.0185
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)10
Glutamate receptor ionotropic, NMDA 2AHomo sapiens (human)0.007
Glutamate receptor ionotropic, NMDA 2BHomo sapiens (human)0.037
Glutamate receptor ionotropic, NMDA 2CHomo sapiens (human)0.007
Glutamate receptor ionotropic, NMDA 3AHomo sapiens (human)0.007

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hawker, DD; Jansen Labby, K; Mataka, JJ; Silverman, RB; Trippier, PC1

Reviews

1 review(s) available for omega-n-methylarginine and cp 101,606

ArticleYear
Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.
    Journal of medicinal chemistry, 2013, Apr-25, Volume: 56, Issue:8

    Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Antioxidants; Calcium Channels; Drug Combinations; Drug Design; Humans; Huntington Disease; Neurodegenerative Diseases; Nitric Oxide Synthase Type I; Oxidative Stress; Parkinson Disease; Protein Folding; Protein Structure, Quaternary; Proteostasis Deficiencies; Receptors, N-Methyl-D-Aspartate

2013